📊 RCKTW Key Takeaways
Is Rocket Pharmaceuticals, Inc.. (RCKTW) a Good Investment?
Rocket Pharmaceuticals is a pre-revenue biotech company with catastrophic burn rate ($190M annually) against minimal cash reserves ($77.6M), implying critical liquidity crisis within ~5 months without external funding. While the balance sheet shows low debt and improving loss trends, the fundamental lack of revenue combined with unsustainable operational burn presents existential risk.
Why Buy Rocket Pharmaceuticals, Inc.. Stock? RCKTW Key Strengths
- Low leverage with zero long-term debt and strong equity base of $277.2M
- Improving loss trajectory with net loss down 13.8% year-over-year
- Exceptional liquidity ratios (6.38x current/quick) provide near-term operational flexibility
RCKTW Stock Risks: Rocket Pharmaceuticals, Inc.. Investment Risks
- Critical cash runway of approximately 5 months at current burn rate ($190M annual operating cash burn vs $77.6M cash)
- Zero revenue indicates failed or stalled pipeline with no near-term commercial viability
- Unsustainable cash burn with no visible path to profitability, creating imminent dilution or bankruptcy risk
Key Metrics to Watch
- Monthly cash burn rate and cash position relative to runway
- Pipeline progress, clinical trial results, and FDA approval milestones
- Funding announcements, partnerships, or strategic transactions
Rocket Pharmaceuticals, Inc.. (RCKTW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.38x current ratio provides a solid financial cushion.
RCKTW Profit Margin, ROE & Profitability Analysis
RCKTW vs Healthcare Sector: How Rocket Pharmaceuticals, Inc.. Compares
How Rocket Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rocket Pharmaceuticals, Inc.. Stock Overvalued? RCKTW Valuation Analysis 2026
Based on fundamental analysis, Rocket Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rocket Pharmaceuticals, Inc.. Balance Sheet: RCKTW Debt, Cash & Liquidity
RCKTW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rocket Pharmaceuticals, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.73 indicates the company is currently unprofitable.
RCKTW Revenue Growth, EPS Growth & YoY Performance
RCKTW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$50.3M | $-0.45 |
| Q2 2025 | N/A | -$61.3M | $-0.62 |
| Q1 2025 | N/A | -$61.3M | $-0.56 |
| Q3 2024 | N/A | -$58.3M | $-0.71 |
| Q2 2024 | N/A | -$58.3M | $-0.74 |
| Q1 2024 | N/A | -$58.3M | $-0.66 |
| Q3 2023 | N/A | -$43.0M | $-0.75 |
| Q2 2023 | N/A | -$43.0M | $-0.82 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rocket Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
RCKTW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rocket Pharmaceuticals, Inc.. (CIK: 0001281895)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RCKTW
What is the AI rating for RCKTW?
Rocket Pharmaceuticals, Inc.. (RCKTW) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RCKTW's key strengths?
Claude: Low leverage with zero long-term debt and strong equity base of $277.2M. Improving loss trajectory with net loss down 13.8% year-over-year.
What are the risks of investing in RCKTW?
Claude: Critical cash runway of approximately 5 months at current burn rate ($190M annual operating cash burn vs $77.6M cash). Zero revenue indicates failed or stalled pipeline with no near-term commercial viability.
What is RCKTW's revenue and growth?
Rocket Pharmaceuticals, Inc.. reported revenue of $0.0.
Does RCKTW pay dividends?
Rocket Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find RCKTW SEC filings?
Official SEC filings for Rocket Pharmaceuticals, Inc.. (CIK: 0001281895) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RCKTW's EPS?
Rocket Pharmaceuticals, Inc.. has a diluted EPS of $-2.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RCKTW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rocket Pharmaceuticals, Inc.. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RCKTW stock overvalued or undervalued?
Valuation metrics for RCKTW: ROE of -80.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RCKTW stock in 2026?
Our dual AI analysis gives Rocket Pharmaceuticals, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RCKTW's free cash flow?
Rocket Pharmaceuticals, Inc..'s operating cash flow is $-190.0M, with capital expenditures of $440.0K.
How does RCKTW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -80.5% (avg: 15%), current ratio 6.38 (avg: 2).